Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 20

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1
Chunk 20
---
 driving the immune medicine platform is our immunosequencing technology that allows us to tap into the massive diversity of the immune repertoire at unparalleled scale and specificity. Our immunosequencing approach utilizes multiplex, bias-controlled PCR to accurately and quantitatively sequence, map, pair and characterize millions of TCRs and BCRs at scale. The proprietary datasets we have generated to date include more than 100,000 signatures of disease (such as cancer and autoimmune conditions) and over 2,000,000 matches of paired TCRs to disease-related antigens.

We are developing a comprehensive map of the interaction between the immune system and disease (the “TCR-Antigen Map”) for use in identifying and validating disease signatures to improve the treatment of various immune-mediated diseases. Supported in part by a collaboration agreement with Microsoft Corporation (“Microsoft”) that we entered into in December 2017 (the “Microsoft Agreement”), we worked with Microsoft through 2024 to enable access to the necessary machine learning and computational infrastructure to build our TCR-Antigen Map, initially for diagnostic purposes. While the collaboration activities have since wound down, we own all data that we generated under the Microsoft Agreement and retain all rights, including commercialization rights, to the algorithms and products that we develop. Given our focus in drug discovery (discussed below), we have strategically repurposed our infrastructure, sizable immunomics database and AI and machine learning models and continue to map at scale TCR sequences to the disease antigens they bind to enable our discovery efforts where we believe we have the greatest opportunity to succeed and create long-term value. We expect to evolve our work with Microsoft and continue to access cloud services and super computing power to help scale our data generation and machine learning modeling efforts. We aim to accelerate development of a ‘digital’ TCR-antigen binding prediction model that will allow us to pursue multiple high-value therapeutic applications and achieve our business goals.

Drug Discovery

 We are focusing our drug discovery programs to develop therapies on our own or in partnership. In these respects, our proprietary data and capabilities uniquely position the IM business to discover and develop differentiated therapeutic candidates such as TCR-based modalities, antibodies and potentially vaccines to better understand immune-mediate biology and treat challenging conditions such as cancer and autoimmune disorders.

11

Under the Genentech Agreement, the IM business supports Genentech in the development of cancer antigen-directed TCR-based cancer cell therapies for the treatment of patients with solid tumors. In 2023, a first FDA-cleared investigational